<unk>  is a kinase inhibitor that is FDA approved for the treatment of patients, in combination with encorafenib, with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.   Common adverse reactions include fatigue, nausea, diarrhea, vomiting, and abdominal pain.
Binimetinib
Cobimetinib
Trametinib
Lestaurtinib
Gefitinib
Stibine
Nilotinib
Molindone